Clair Raises $11.6M to Build the First Continuous Hormone Monitor for Women
BiohackingContinuous glucose monitoring changed how people with diabetes — and later, biohackers — understood metabolic patterns. Clair is attempting an analogous shift for female hormone tracking: a wrist-worn device that infers estrogen, progesterone, LH, and FSH levels continuously, without blood draws, across whatever the real hormonal landscape actually looks like, not the four-phase simplification in most physiology textbooks.
What Happened
Clair Health, a San Francisco-based startup co-founded by Abhinav Agarwal (CTO) and Jenny Duan, closed a seed round bringing total funding to $11.6 million, led by Khosla Ventures with participation from a16z speedrun. The capital extends the runway to a November 2026 launch.
The device combines 10 biosensors with machine learning to infer hormonal activity across four key hormones: estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Rather than measuring hormone levels directly from interstitial fluid or blood, Clair’s system uses over 130 proprietary biomarkers — physiological effects of hormonal changes rather than hormone concentrations themselves — to reconstruct hormonal state continuously.
In beta testing, the Clair device identified nine distinct hormonal sub-phases across the menstrual cycle, compared to the standard four-phase framework taught in physiology curricula. Whether those additional phases have clinical significance is yet to be established in peer-reviewed research, but the granularity alone shifts the monitoring paradigm: existing wearables give you heart rate and sleep stage data without the hormonal context that shapes both of those readings for most of each month.
Why It Matters
Current wearables in the longevity tracking stack treat physiological signals from women as variant-free across time. Heart rate variability thresholds, sleep quality baselines, and recovery scores are typically set without accounting for where someone is in their hormonal cycle — a design gap that produces interpretive noise for any user whose hormonal state significantly modulates those signals.
The conditions most directly impacted by the monitoring gap are PCOS, endometriosis, and fertility tracking — contexts where knowing whether someone is in the luteal phase or experiencing an LH surge has direct clinical relevance. Continuous data across those cycles, rather than periodic blood draws that capture a single point in time, could support earlier pattern detection for conditions that currently take years to diagnose on average.
The non-invasive approach is the key technical bet. Companies have tried and largely failed to build accurate continuous hormone monitoring because hormone concentration measurement requires a biological sample. Clair’s system sidesteps that by inferring hormonal state from physiological correlates — a machine learning approach that trades direct measurement for signal integration across dozens of proxy biomarkers.
The So What
Clair launches into a wearable market that has been measuring physiological data without hormonal context for over a decade. If the accuracy holds across diverse users in post-beta conditions, continuous non-invasive hormone monitoring closes a gap that current health tracking has treated as intractable. The November 2026 launch will be the first real test of whether the approach generalizes beyond the controlled beta environment. For anyone managing a condition where hormonal timing is clinically relevant — or for biohackers whose recovery protocols aren’t accounting for the cycle — Clair is worth watching before the broader wearable market catches up to this measurement category.
Source: Longevity Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →